Claims for Patent: 8,071,087

Summary for Patent: 8,071,087

Title:	Reovirus for the treatment of cellular proliferative disorders
Abstract:	Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
Inventor(s):	Lee; Patrick W. K. (Halifax, CA), Strong; James (Calgary, CA), Coffey; Matthew C. (Calgary, CA)
Assignee:	Oncolytics Biotech Inc. (Calgary, Alberta, CA)
Application Number:	12/841,550
Patent Claims:	1. A kit comprising (i) a reovirus and (ii) a chemotherapeutic agent wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, epirubicin, doxorubicin, herceptin, etoposide, pregnasome, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, interferons, aromatase inhibitors, progestational agents and Luteinizing hormone-releasing hormone (LHRH) analogs. 2. The kit of claim 1, wherein the reovirus is in a pharmaceutical composition. 3. The kit of claim 1, wherein the chemotherapeutic agent is in a pharmaceutical composition. 4. The kit of claim 2, wherein the reovirus is formulated in a unit dosage form. 5. The kit of claim 4, wherein the kit comprises one unit dose of reovirus. 6. The kit of claim 4, wherein the kit comprises more than one unit dose of reovirus. 7. The kit of claim 4, wherein the unit dose of reovirus comprises from about 10.sup.2 pfu to about 10.sup.13 pfu. 8. The kit of claim 1, wherein the reovirus is a mammalian reovirus. 9. The kit of claim 8, wherein the mammalian reovirus is a human reovirus. 10. The kit of claim 1, wherein the reovirus is selected from the group consisting of serotype 1 reovirus, serotype 2 reovirus and serotype 3 reovirus. 11. The kit of claim 1, wherein the chemotherapeutic agent is taxol. 12. The kit of claim 1, wherein the chemotherapeutic agent is cisplatin. 13. The kit of claim 1, wherein the chemotherapeutic agent is cyclophosphamide.

Details for Patent 8,071,087

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2019-02-24
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2019-02-24